Related Experiment Video

Updated: Mar 16, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.4K

A focused compound screen highlights the significance of epidermal growth factor receptor signalling in chordoma

Mira Ghaly1, Corin Seelemann1, Arezu Jahani-Asl1

  • 1Department of Oncology, Faculty of Medicine, McGill University and Lady Davis Medical Research Institute, Jewish General Hospital, Montreal, Quebec, Canada.

The Journal of Pathology
|August 20, 2016
PubMed

Insights

Chordoma, a rare bone cancer, shows resistance to chemotherapy. Targeting epidermal growth factor receptor (EGFR) and MET signaling with combined inhibitors offers a promising strategy to overcome this resistance in chordoma patients.

Area of Science:

  • Oncology
  • Cancer Biology
  • Pharmacology

Background:

  • Chordoma is a rare primary bone cancer with limited therapeutic strategies.
  • Recurrent and metastatic chordoma exhibits significant chemoresistance, necessitating novel treatment approaches.
  • Epidermal growth factor receptor (EGFR) signaling is implicated in chordoma progression.

Purpose of the Study:

  • To investigate the role of EGFR signaling in chordoma.
  • To evaluate the efficacy of EGFR inhibitors, alone and in combination with MET inhibitors, for treating chemoresistant chordoma.

Main Methods:

  • Focused compound drug screening was employed.
  • The study assessed the impact of EGFR and MET inhibitors on chordoma cell growth, particularly in resistant models.

Main Results:

  • EGFR signaling is significant in chordoma.
  • EGFR inhibitors show potential for chordoma treatment.
  • Combining EGFR and MET inhibitors demonstrated a synergistic effect on inhibiting resistant chordoma cell growth.

Conclusions:

  • Targeting EGFR signaling presents a viable therapeutic avenue for chordoma.
  • Combined inhibition of EGFR and MET offers a promising strategy to overcome chemoresistance in chordoma.
Keywords:
EGFR inhibitorsMET inhibitorschordomacompound drug screencrizotinibmetsapitinib

More Related Videos

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.7K
Isolation of Whole Cell Protein Lysates from Mouse Facial Processes and Cultured Palatal Mesenchyme Cells for Phosphoprotein Analysis07:26

Isolation of Whole Cell Protein Lysates from Mouse Facial Processes and Cultured Palatal Mesenchyme Cells for Phosphoprotein Analysis

Published on: April 1, 2022

2.5K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
88.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.9K
Notch Signaling Pathway03:14

Notch Signaling Pathway

The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
6.8K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.8K